Metformin Hydrochloride Tablets

This product is a hypoglycemic drug. This product can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and HbAlc can be reduced by 1%~2%. The mechanism of this product in lowering blood sugar may be: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization. 2. Increase the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc. 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output. 4. Inhibit the uptake of glucose by intestinal wall cells. 5. Inhibit the biosynthesis and storage of cholesterol and reduce blood triglyceride and total cholesterol levels. Unlike the effect of insulin, this product has no effect on promoting fat synthesis and no obvious hypoglycemic effect on normal people. It generally does not cause hypoglycemia when used alone for type 2 diabetes.

250mg metformin hydrochloride 1.25mg glibenclamide.

This product is a sugar-coated tablet or a film-coated tablet, which appears white after removing the coating.

It is used for patients with type 2 diabetes whose blood sugar levels are not satisfactorily controlled by diet control and/or exercise therapy alone; it can be used as a second-line medication for patients with type 2 diabetes whose blood sugar levels are not satisfactorily controlled by treatment with sulfonylureas or metformin hydrochloride alone.

Please use the medicine under the guidance of a doctor. For patients receiving first-time treatment: Adults: Initial dosage is one tablet each time, one to two times a day, taken during meals; or follow the doctor's advice; Children: The use and dosage must be determined by the doctor. For patients who used sulfonylurea hypoglycemic drugs or metformin before using this product; Adults: Initial dosage is two tablets each time, twice a day, taken during the morning and evening meals; or follow the doctor's advice. Children: The use and dosage must be determined by the hospital.

1 Common symptoms include: nausea, vomiting, diarrhea, metallic taste in the mouth. 2 Sometimes there is weakness, tiredness, dizziness, and rash. 3 Although the incidence of lactic acidosis is very low, it should be paid attention to. Clinical manifestations include vomiting, abdominal pain, hyperventilation, mental disorder, and increased lactic acid concentration in the blood that cannot be explained by ureaemia, ketoacidosis, or salicylic acid poisoning. 4 It can reduce the absorption of vitamin B12, reduce hemoglobin, produce megaloblastic anemia, and also cause malabsorption.

The following conditions should not be used: 1. Type II diabetes with ketoacidosis, liver and kidney dysfunction (serum creatinine exceeds 1.5 mg/dl), pulmonary dysfunction, heart failure, acute myocardial infarction, severe infection and trauma, major surgery, and clinical hypotension and hypoxia. 2. Diabetes with severe chronic complications (such as diabetic nephropathy, diabetic fundus lesions). 3. Before intravenous pyelography or arterial angiography. 4. Alcoholics. 5. Patients with severe heart and lung diseases. 6. Patients with vitamin B12, folic acid and iron deficiency. 7. Patients with poor systemic condition (such as malnutrition, dehydration).

Precautions for children: The maximum daily dose of this product for patients with type 2 diabetes aged 10-16 years is 2000 mg. This product is not recommended for children under 10 years old. Precautions for pregnancy and lactation: This product is not recommended for pregnant women. Lactating women should use this product with caution. If this product must be used, breastfeeding should be stopped. Precautions for the elderly: Elderly patients over 65 years old should use this product with caution and have their renal function checked regularly. The maximum dose is usually not used. This product is not recommended for patients over 80 years old unless their creatinine clearance test shows that their renal function is not reduced.

1. When used in combination with insulin, the hypoglycemic effect is enhanced, and the dosage should be adjusted. 2. This product can enhance the anticoagulant effect of anticoagulants (such as warfarin), which may cause bleeding tendency. 3. Cimetidine can increase the bioavailability of this product and reduce the renal clearance rate, so the dosage of this product should be reduced.

Keep away from light and store in a sealed container.

0.25 g

24 months.

Suzhou Dawnrays Pharmaceutical Co., Ltd.

• Founded in:

  1995-12-08

• Address:

  No. 268, Minfeng Road, Wuzhong Economic Development Zone, Suzhou

• Tax NO.:

  913205006283933800

• Registered Funds:

  $131.5 million

• Website:

  Log in to view

• Email:

  Log in to view